Shares of Aerie Pharmaceuticals were soaring more than 35 percent after the company announced Phase III data for its combination glaucoma drug, Roclatan, met efficacy endpoints.
A bill passed by U.S. House Republicans would cause 23 million people to lose healthcare coverage by 2026 while de-stabilizing health insurance markets in some states and making it hard for sick people to buy insurance, a budget watchdog agency said.
Merck & Co.’s Keytruda became the first cancer drug FDA-approved based on a patients’ specific genetic traits regardless of where in the body the disease originated.
The U.S. FDA accepted a supplemental BLA that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma after prior sorafenib therapy.
Abbott Laboratories is recalling for more than 28,000 of its HeartMate II blood pumps after 26 patients died after attempting to exchange controllers while away from the hospital.
tranSMART Foundation Teams With IBM to Bring Translational Medicine Data to Scientists, Merges With I2B2
Biotech researchers looking to harness the power of big data could have an easier time with the new partnership between IBM and the tranSMART Foundation, a Massachusetts-based nonprofit organization founded in 2012 with a goal of providing a platform to share pre-competitive data for use in designing transformational medicines.
Novartis AG, headquartered in Basel, Switzerland, filed with the state of New Jersey that it plans to lay off more than 200 workers. The company, whose U.S. headquarters are in East Hanover, NJ, is undergoing operational changes.
Shares of Neurocrine Biosciences Inc. were down more than 8 percent after its Phase II Tourette syndrome drug Ingrezza (valbenazine) failed to meet its primary endpoint due to what the company said was inadequate dosing.
Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.
President Donald Trump’s 2018 budget proposal takes a machete to the spending plans of nationally funded health programs that fund medical research, disease prevention and insurance plans.